SAB Biotherapeutics (SABS) Accumulated Depreciation & Amortization (2020 - 2025)
Historic Accumulated Depreciation & Amortization for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $16.8 million.
- SAB Biotherapeutics' Accumulated Depreciation & Amortization rose 2145.64% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 2145.64%. This contributed to the annual value of $14.6 million for FY2024, which is 4703.52% up from last year.
- As of Q3 2025, SAB Biotherapeutics' Accumulated Depreciation & Amortization stood at $16.8 million, which was up 2145.64% from $16.1 million recorded in Q2 2025.
- In the past 5 years, SAB Biotherapeutics' Accumulated Depreciation & Amortization registered a high of $16.8 million during Q3 2025, and its lowest value of -$16.2 million during Q1 2022.
- Over the past 5 years, SAB Biotherapeutics' median Accumulated Depreciation & Amortization value was $9.5 million (recorded in 2023), while the average stood at $6.2 million.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first crashed by 9661.39% in 2021, then soared by 15030.71% in 2023.
- Quarter analysis of 5 years shows SAB Biotherapeutics' Accumulated Depreciation & Amortization stood at -$16.0 million in 2021, then surged by 139.35% to $6.3 million in 2022, then soared by 57.87% to $9.9 million in 2023, then surged by 47.04% to $14.6 million in 2024, then increased by 15.42% to $16.8 million in 2025.
- Its Accumulated Depreciation & Amortization was $16.8 million in Q3 2025, compared to $16.1 million in Q2 2025 and $15.3 million in Q1 2025.